Journal of Molecular Science

www.jmolecularsci.com

ISSN:1000-9035

Mechanistic Insights into Autophagy Dysfunction in Neurodegenerative and Metabolic Disorders: Molecular Pathways, Cellular Implications, and Therapeutic Perspectives

Emily Grace Taylor, George Henry Wilson, Charlotte Elizabeth Davies

Article Information

Received: 21-10-2023 Revised: 05-11-2023 Accepted: 25-11-2023 Published: 20-12-2023

Keywords

Autophagy Alzheimer's Parkinson's, and huntington's disease

ABSTRACT

Autophagy is a crucial intracellular degradation pathway responsible for maintaining cellular homeostasis by recycling damaged organelles and misfolded proteins. Dysregulation of autophagy has been implicated in various neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's disease, as well as metabolic disorders such as diabetes and obesity. This review aims to provide mechanistic insights into how autophagy dysfunction contributes to disease pathology, highlighting key molecular pathways, cellular consequences, and potential therapeutic interventions. We integrate findings from genetic, biochemical, and pharmacological studies to elucidate the role of autophagy in neuronal survival, protein clearance, and metabolic regulation. Understanding these mechanisms offers promising avenues for novel therapeutic strategies to mitigate disease progression.

INTRODUCTION:

Autophagy is an essential lysosomal degradation process that removes dysfunctional organelles and aggregates, thereby preserving cellular function. It plays a critical role in various physiological processes, including metabolism, immune response, and neuronal survival. Defective autophagy is a hallmark of several neurodegenerative and metabolic disorders. contributing to the accumulation of toxic protein aggregates, mitochondrial dysfunction, and metabolic imbalances. This article explores the molecular mechanisms of autophagy dysfunction in neurodegenerative and metabolic diseases. We analyze the impact of key regulatory proteins, such as mTOR, AMPK, and TFEB, on autophagy modulation and discuss how therapeutic interventions targeting autophagy can potentially alleviate disease symptoms.

Molecular Mechanisms of Autophagy Dysfunction

Role of mTOR and AMPK Signaling in Autophagy Regulation

©2023 The authors

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.(https://creativecommons.org/licenses /by-nc/4.0/)

Journal of Molecular Science




Fig.mTOR Signaling in Autophagy Regulation




Fig.AMPK Signaling in Autophagy Regulation

The mechanistic target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) serve as master regulators of autophagy. mTOR inhibits autophagy under nutrient-rich conditions, while AMPK activates autophagy in response to energy depletion. Dysregulation of these pathways is associated with impaired autophagic flux in neurodegenerative and metabolic disorders.

Signaling Pathway	Function in Autophagy	Disease Implications
mTOR	Inhibits autophagy	Hyperactivation linked to neurodegeneration
AMPK	Activates autophagy	Deficiency contributes to metabolic disorders
TFEB	Enhances lysosomal biogenesis	Dysregulation impairs autophagic clearance

Lysosomal Dysfunction and Impaired Autophagic Flux:

Lysosomal degradation is the final step in the autophagy process. Mutations in lysosomal enzymes, such as glucocerebrosidase (GCase) in Parkinson's disease and cathepsins in Alzheimer's disease, lead to defective autophagic clearance. In metabolic disorders, lysosomal dysfunction contributes to lipid and glycogen accumulation, further exacerbating disease pathology.

Autophagy Dysfunction in Neurodegenerative Diseases:

Alzheimer's Disease (AD):

Autophagy failure in AD leads to the accumulation

of amyloid-beta (A β) and hyperphosphorylated tau, contributing to neuronal toxicity. Studies show that upregulating autophagy through rapamycin or TFEB activation reduces A β burden and improves cognitive function in AD models.

Parkinson's Disease (PD)

In PD, mutations in autophagy-related genes such as PINK1 and Parkin result in defective mitophagy, leading to mitochondrial dysfunction and dopaminergic neuron degeneration. Pharmacological activation of autophagy has been proposed as a neuroprotective strategy.

Huntington's Disease (HD)

HD is characterized by the aggregation of mutant huntingtin (mHTT) protein due to impaired autophagic degradation. Restoring autophagy by inhibiting mTOR or activating AMPK shows promise in reducing mHTT toxicity.

Autophagy Dysfunction in Metabolic Disorders Type 2 Diabetes Mellitus (T2DM)

Autophagy plays a key role in pancreatic β -cell survival and insulin sensitivity. In T2DM, defective autophagy contributes to endoplasmic reticulum (ER) stress and insulin resistance. Enhancing autophagy through AMPK activation improves glucose metabolism and β -cell function.

Obesity and Lipid Metabolism

Autophagy regulates lipid turnover through lipophagy. Impaired autophagic degradation of lipid droplets leads to excessive lipid accumulation and metabolic dysfunction in obesity. Pharmacological approaches targeting autophagy have shown potential in modulating lipid homeostasis.

Therapeutic Targeting of Autophagy in Disease Management

Pharmacological Modulation of Autophagy

Various compounds, including rapamycin, metformin, and spermidine, have been explored to modulate autophagy in neurodegenerative and metabolic disorders. These agents either inhibit mTOR or activate AMPK, enhancing autophagic flux and improving cellular homeostasis.

Drug	Mechanism	Target Disease
Rapamycin	mTOR inhibition	Alzheimer's, Parkinson's
Metformin	AMPK activation	Diabetes, Obesity
Spermidine	TFEB activation	Neurodegeneration

Gene Therapy Approaches

CRISPR-based gene editing and viral vectormediated gene delivery hold promise for correcting autophagy-related genetic defects. Targeting TFEB and other autophagy regulators may offer long-term benefits in treating these disorders.

Journal of Molecular Science

CONCLUSION:

Autophagy dysfunction is a common pathological feature of neurodegenerative and metabolic disorders. Understanding the molecular mechanisms underlying impaired autophagy provides a basis for developing targeted therapeutic interventions. Future research should focus on optimizing autophagy-modulating strategies to achieve diseasespecific benefits while minimizing potential adverse effects.

REFERENCES:

- 1. Mizushima, N., & Levine, B. (2020). "Autophagy in human diseases." *Cell.*
- Klionsky, D. J., et al. (2016). "Guidelines for the use and interpretation of assays for monitoring autophagy." *Autophagy.*
- 3. Nixon, R. A. (2013). "The role of autophagy in neurodegenerative disease." *Nat Med.*
- Hara, T., et al. (2006). "Suppression of basal autophagy in neural cells causes neurodegeneration in mice." *Nature*.
- 5. Zhang, X., et al. (2019). "Lysosomal dysfunction in neurodegenerative diseases." *J Cell Sci.*
- 6. Rubinsztein, D. C., et al. (2012). "Autophagy and its role in neurodegeneration." *Nat Rev Neurosci.*
- 7. Martinez-Lopez, N., et al. (2013). "Autophagy in the regulation of lipid metabolism." *Trends Endocrinol Metab.*
- Singh, R., & Cuervo, A. M. (2011). "Autophagy in metabolic control and insulin resistance." *Mol Cell.*
- Sardiello, M., et al. (2009). "A gene network regulating lysosomal biogenesis and function." *Science*.
- 10. Komatsu, M., et al. (2006). "Impairment of autophagy leads to hepatocellular injury." *J Cell Biol.*
- 11. Fang, E. F., et al. (2019). "NAD+ metabolism and autophagy in aging and disease." *Cell Metab.*
- 12. Moscat, J., et al. (2007). "p62 and autophagy in chronic diseases." *Trends Mol Med.*
- 13. De Duve, C., & Wattiaux, R. (1966). "Functions of lysosomes." Annu Rev Physiol.
- 14. Carroll, B., et al. (2015). "Regulation of autophagy in neurodegeneration." *J Pathol.*
- 15. Madeo, F., et al. (2015). "Nutritional aspects of autophagy modulation in aging and disease." *Autophagy*.